{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:11:48Z","timestamp":1794305508019,"version":"4.9.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2018-I2M-2-002"],"award-info":[{"award-number":["2018-I2M-2-002"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["SEACOVARIANTS"],"award-info":[{"award-number":["SEACOVARIANTS"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["101122\/Z\/13\/Z"],"award-info":[{"award-number":["101122\/Z\/13\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009187","name":"RCUK | MRC | Medical Research Foundation","doi-asserted-by":"publisher","award":["MR\/N00065X\/1"],"award-info":[{"award-number":["MR\/N00065X\/1"]}],"id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Under pressure from neutralising antibodies induced by vaccination or infection the SARS-CoV-2 spike gene has become a hotspot for evolutionary change, leading to the failure of all mAbs developed for clinical use. Most potent antibodies bind to the receptor binding domain which has become heavily mutated. Here we study responses to a conserved epitope in sub-domain-1 (SD1) of spike which have become more prominent because of mutational escape from antibodies directed to the receptor binding domain. Some SD1 reactive mAbs show potent and broad neutralization of SARS-CoV-2 variants. We structurally map the dominant SD1 epitope and provide a mechanism of action by blocking interaction with ACE2. Mutations in SD1 have not been sustained to date, but one, E554K, leads to escape from mAbs. This mutation has now emerged in several sublineages including BA.2.86, reflecting selection pressure on the virus exerted by the increasing prominence of the anti-SD1 response.<\/jats:p>","DOI":"10.1038\/s41467-024-46982-6","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T14:07:39Z","timestamp":1711634859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7188-5243","authenticated-orcid":false,"given":"Daming","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyada","family":"Supasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4850-9709","authenticated-orcid":false,"given":"Aiste","family":"Dijokaite-Guraliuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M. E.","family":"Duyvesteyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneeswaran","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4502-2209","authenticated-orcid":false,"given":"Alexander J.","family":"Mentzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raksha","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanwisa","family":"Dejnirattisai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7978-3815","authenticated-orcid":false,"given":"Nigel","family":"Temperton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4307-9161","authenticated-orcid":false,"given":"Paul","family":"Klenerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5665-6293","authenticated-orcid":false,"given":"Susanna J.","family":"Dunachie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9754-5303","authenticated-orcid":false,"given":"Elizabeth E.","family":"Fry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3416-9480","authenticated-orcid":false,"given":"Juthathip","family":"Mongkolsapaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3426-4210","authenticated-orcid":false,"given":"David I.","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3549-4309","authenticated-orcid":false,"given":"Gavin R.","family":"Screaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"46982_CR1","unstructured":"WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int\/ (2024)."},{"key":"46982_CR2","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","volume":"184","author":"W Dejnirattisai","year":"2021","unstructured":"Dejnirattisai, W. et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184, 2939\u20132954 e2939 (2021).","journal-title":"Cell"},{"key":"46982_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112271","volume":"42","author":"A Dijokaite-Guraliuc","year":"2023","unstructured":"Dijokaite-Guraliuc, A. et al. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses. Cell Rep. 42, 112271 (2023).","journal-title":"Cell Rep."},{"key":"46982_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111903","volume":"42","author":"J Huo","year":"2023","unstructured":"Huo, J. et al. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. Cell Rep. 42, 111903 (2023).","journal-title":"Cell Rep."},{"key":"46982_CR5","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41564-022-01235-4","volume":"7","author":"P He","year":"2022","unstructured":"He, P. et al. SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope. Nat. Microbiol. 7, 1635\u20131649 (2022).","journal-title":"Nat. Microbiol."},{"key":"46982_CR6","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.cell.2021.02.032","volume":"184","author":"W Dejnirattisai","year":"2021","unstructured":"Dejnirattisai, W. et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell 184, 2183\u20132200.e2122 (2021).","journal-title":"Cell"},{"key":"46982_CR7","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.cell.2022.05.014","volume":"185","author":"R Nutalai","year":"2022","unstructured":"Nutalai, R. et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell 185, 2116\u20132131 (2022).","journal-title":"Cell"},{"key":"46982_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443\u2013449 (2020).","journal-title":"Nature"},{"key":"46982_CR9","doi-asserted-by":"publisher","first-page":"e70658","DOI":"10.7554\/eLife.70658","volume":"10","author":"MI Barton","year":"2021","unstructured":"Barton, M. I. et al. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. Elife 10, e70658 (2021).","journal-title":"Elife"},{"key":"46982_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22926-2","volume":"12","author":"Y Guo","year":"2021","unstructured":"Guo, Y. et al. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. Nat. Commun. 12, 2623 (2021).","journal-title":"Nat. Commun."},{"key":"46982_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1126\/science.abd2321","volume":"369","author":"M Yuan","year":"2020","unstructured":"Yuan, M. et al. Structural basis of a shared antibody response to SARS-CoV-2. Science 369, 1119\u20131123 (2020).","journal-title":"Science"},{"key":"46982_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"46982_CR13","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41594-020-0480-y","volume":"27","author":"D Zhou","year":"2020","unstructured":"Zhou, D. et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat. Struct. Mol. Biol. 27, 950\u2013958 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"46982_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.chom.2020.06.010","volume":"28","author":"J Huo","year":"2020","unstructured":"Huo, J. et al. Neutralization of SARS-CoV-2 by destruction of the prefusion Spike. Cell Host Microbe 28, 445\u2013454 (2020).","journal-title":"Cell Host Microbe"},{"key":"46982_CR15","doi-asserted-by":"publisher","first-page":"e159062","DOI":"10.1172\/JCI159062","volume":"132","author":"N Suryadevara","year":"2022","unstructured":"Suryadevara, N. et al. An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer. J. Clin. Invest. 132, e159062 (2022).","journal-title":"J. Clin. Invest."},{"key":"46982_CR16","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.chom.2021.03.005","volume":"29","author":"G Cerutti","year":"2021","unstructured":"Cerutti, G. et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe 29, 819\u2013833.e817 (2021).","journal-title":"Cell Host Microbe"},{"key":"46982_CR17","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.abc6952","volume":"369","author":"X Chi","year":"2020","unstructured":"Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650\u2013655 (2020).","journal-title":"Science"},{"key":"46982_CR18","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1016\/j.immuni.2023.09.003","volume":"56","author":"L Liu","year":"2023","unstructured":"Liu, L. et al. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. Immunity 56, 2442\u20132455.e2448 (2023).","journal-title":"Immunity"},{"key":"46982_CR19","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.cell.2021.02.033","volume":"184","author":"P Supasa","year":"2021","unstructured":"Supasa, P. et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 184, 2201\u20132211.e2207 (2021).","journal-title":"Cell"},{"key":"46982_CR20","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","volume":"184","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220\u20134236.e4213 (2021).","journal-title":"Cell"},{"key":"46982_CR21","doi-asserted-by":"crossref","unstructured":"Khan, K. et al. Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant. Nat. Commun. 14, 8078 (2023).","DOI":"10.1038\/s41467-023-43703-3"},{"key":"46982_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","volume":"186","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186, 279\u2013286.e278 (2023).","journal-title":"Cell"},{"key":"46982_CR23","doi-asserted-by":"crossref","unstructured":"Khare, S. et al. GISAID\u2019s Role in Pandemic Response. China CDC Weekly, 3, 1049\u20131051 (2021).","DOI":"10.46234\/ccdcw2021.255"},{"key":"46982_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5694\/mja2.50569","volume":"212","author":"L Caly","year":"2020","unstructured":"Caly, L. et al. Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med. J. Aust. 212, 459\u2013462 (2020).","journal-title":"Med. J. Aust."},{"key":"46982_CR25","unstructured":"Di Genova, C. et al. Production, titration, neutralisation and storage of SARS-CoV-2 lentiviral pseudotypes. figshare (2020)."},{"key":"46982_CR26","unstructured":"SARS-CoV-2 Variant Classifications and Definitions. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/variants\/variant-classifications.html (2023)."},{"key":"46982_CR27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"46982_CR28","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.chom.2021.04.010","volume":"29","author":"SM Lok","year":"2021","unstructured":"Lok, S. M. An NTD supersite of attack. Cell Host Microbe 29, 744\u2013746 (2021).","journal-title":"Cell Host Microbe"},{"key":"46982_CR29","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/ni.3849","volume":"18","author":"E Fernandez","year":"2017","unstructured":"Fernandez, E. et al. Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. Nat. Immunol. 18, 1261\u20131269 (2017).","journal-title":"Nat. Immunol."},{"key":"46982_CR30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41586-022-04581-9","volume":"604","author":"Q Hong","year":"2022","unstructured":"Hong, Q. et al. Molecular basis of receptor binding and antibody neutralization of Omicron. Nature 604, 546\u2013552 (2022).","journal-title":"Nature"},{"key":"46982_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111276","volume":"40","author":"J Seow","year":"2022","unstructured":"Seow, J. et al. A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination. Cell Rep. 40, 111276 (2022).","journal-title":"Cell Rep."},{"key":"46982_CR32","doi-asserted-by":"publisher","first-page":"eade0958","DOI":"10.1126\/sciimmunol.ade0958","volume":"8","author":"F Bianchini","year":"2023","unstructured":"Bianchini, F. et al. Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein. Sci. Immunol. 8, eade0958 (2023).","journal-title":"Sci. Immunol."},{"key":"46982_CR33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/22221751.2021.2024455","volume":"11","author":"S Xu","year":"2022","unstructured":"Xu, S. et al. Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein. Emerg. Microbes Infect. 11, 351\u2013367 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"46982_CR34","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","volume":"184","author":"D Zhou","year":"2021","unstructured":"Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348\u20132361.e2346 (2021).","journal-title":"Cell"},{"key":"46982_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","volume":"185","author":"W Dejnirattisai","year":"2022","unstructured":"Dejnirattisai, W. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467\u2013484.e415 (2022).","journal-title":"Cell"},{"key":"46982_CR36","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2021","unstructured":"Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med. 384, 238\u2013251 (2021).","journal-title":"N. Engl. J. Med."},{"key":"46982_CR37","doi-asserted-by":"publisher","first-page":"110812","DOI":"10.1016\/j.celrep.2022.110812","volume":"39","author":"K Westendorf","year":"2022","unstructured":"Westendorf, K. et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 39, 110812 (2022).","journal-title":"Cell Rep."},{"key":"46982_CR38","doi-asserted-by":"publisher","first-page":"n2860","DOI":"10.1136\/bmj.n2860","volume":"375","author":"E Mahase","year":"2021","unstructured":"Mahase, E. Covid-19: AstraZeneca says its antibody drug AZD7442 is effective for preventing and reducing severe illness. BMJ 375, n2860 (2021).","journal-title":"BMJ"},{"key":"46982_CR39","doi-asserted-by":"crossref","unstructured":"Asor R. et al. Cooperativity and induced oligomerization control the interaction of SARS-CoV-2 with its cellular receptor and patient-derived antibodies. Biophys J. 123, 313a (2024).","DOI":"10.1016\/j.bpj.2023.11.1931"},{"key":"46982_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/B978-0-12-385120-8.00015-2","volume":"498","author":"DG Gibson","year":"2011","unstructured":"Gibson, D. G. Enzymatic assembly of overlapping DNA fragments. Methods Enzymol. 498, 349\u2013361 (2011).","journal-title":"Methods Enzymol."},{"key":"46982_CR41","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","volume":"9","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 9, 680\u2013686 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"46982_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.chom.2021.11.013","volume":"30","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. Cell, Host Microbe 30, 53\u201368 (2021).","journal-title":"Cell, Host Microbe"},{"key":"46982_CR43","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422\u20132433.e2413 (2022).","journal-title":"Cell"},{"key":"46982_CR44","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"46982_CR45","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"46982_CR46","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jsb.2015.08.007","volume":"192","author":"JL Rubinstein","year":"2015","unstructured":"Rubinstein, J. L. & Brubaker, M. A. Alignment of cryo-EM movies of individual particles by optimization of image translations. J. Struct. Biol. 192, 188\u2013195 (2015).","journal-title":"J. Struct. Biol."},{"key":"46982_CR47","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41592-020-00990-8","volume":"17","author":"A Punjani","year":"2020","unstructured":"Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17, 1214\u20131221 (2020).","journal-title":"Nat. Methods"},{"key":"46982_CR48","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nmeth.2115","volume":"9","author":"SH Scheres","year":"2012","unstructured":"Scheres, S. H. & Chen, S. Prevention of overfitting in cryo-EM structure determination. Nat. Methods 9, 853\u2013854 (2012).","journal-title":"Nat. Methods"},{"key":"46982_CR49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF chimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"46982_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-10-421","volume":"10","author":"C Camacho","year":"2009","unstructured":"Camacho, C. et al. BLAST+: architecture and applications. BMC Bioinforma. 10, 421 (2009).","journal-title":"BMC Bioinforma."},{"key":"46982_CR51","first-page":"43","volume":"4","author":"P Afonine","year":"2013","unstructured":"Afonine, P., Headd, J., Terwilliger, T. & Adams, P. New tool: phenix. real_space_refine. Comput. Crystallogr. Newsl. 4, 43\u201344 (2013).","journal-title":"Comput. Crystallogr. Newsl."},{"key":"46982_CR52","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46982-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46982-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46982-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T15:03:21Z","timestamp":1711638201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46982-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["46982"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-46982-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2684849\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.R.S. sits on the GSK Vaccines Scientific Advisory Board, consults for AstraZeneca and is a founder member of RQ Biotechnology. D.I.S. consults for AstraZeneca. Oxford University holds intellectual property related to SARS-CoV-2 mAbs discovered in G.R.S\u2019s laboratory. S.J.D. is a Scientific Advisor to the Scottish Parliament on COVID-19. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2734"}}